Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to E

Indication
Advanced Melanoma

Other upcoming events for EIKN

Phase 3 ReadoutPhase 3 Topline: A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in C

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to E — EIKN Phase 3 Readout | BioSniper